Fundz

Aurinia completes acquisition of Kezar Life Sciences

PUBLIC · AUPHAug 29, 2026

Acquiring Company

Aurinia Pharmaceuticals

Acquired Company

Kezar Life Sciences

CaliforniaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsBiopharma

Description

Aurinia Pharmaceuticals has successfully acquired Kezar Life Sciences through a cash and stock merger. Under the terms, former shareholders of Kezar will receive $6.9550 in cash plus one share in the post-merger entity. This merger offers a combined value that includes both immediate cash compensation and equity participation in the new company.

Who to call at Aurinia Pharmaceuticals, and when

When Aurinia Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Aurinia Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Aurinia Pharmaceuticals, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Aurinia Pharmaceuticals

About

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of kidney diseases. Their lead product, LUPKYNIS® (voclosporin), is specifically designed to treat lupus nephritis. Aurinia is committed to advancing scientific understanding and improving patient outcomes in nephrology. The company's mission emphasizes addressing unmet medical needs in patients with rare diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Aurinia Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Aurinia Pharmaceuticals's next move

Learn about Strategic plan

Frequently asked

Who acquired Kezar Life Sciences?

Kezar Life Sciences was acquired by Aurinia Pharmaceuticals. The deal was reported on August 29, 2026. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of kidney diseases. Aurinia Pharmaceuticals is publicly traded (AUPH) and operates in Biotechnology.

When did Aurinia Pharmaceuticals acquire Kezar Life Sciences?

Aurinia Pharmaceuticals's acquisition of Kezar Life Sciences was reported on August 29, 2026. Aurinia Pharmaceuticals has successfully acquired Kezar Life Sciences through a cash and stock merger. Under the terms, former shareholders of Kezar will receive $6.9550 in cash plus one share in the post-merger entity. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Kezar Life Sciences do?

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. It is privately held, operating in Biotechnology, and is based in California.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.